Selective Inhibitors of Nuclear Export (SINE) compounds block proliferation and migration of triple negative breast cancer cells by restoring expression of ARRDC3.

Soung, Young Hwa; Kashyap, Trinayan; Nguyen, Thalia; Yadav, Garima; Chang, Hua; Landesman, Yosef; Chung, Jun

Soung, Young Hwa; Kashyap, Trinayan; Nguyen, Thalia; Yadav, Garima; Chang, Hua; Landesman, Yosef; Chung, Jun.

Afiliación

Soung YH; Department of Pathology, Stony Brook Medicine, Stony Brook, NY 11794, USA.
Kashyap T; Karyopharm Therapeutics, Inc. Newton, MA 02459, USA.
Nguyen T; University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA.
Yadav G; Department of Pathology, Stony Brook Medicine, Stony Brook, NY 11794, USA.
Chang H; Karyopharm Therapeutics, Inc. Newton, MA 02459, USA.
Landesman Y; Karyopharm Therapeutics, Inc. Newton, MA 02459, USA.
Chung J; Department of Pathology, Stony Brook Medicine, Stony Brook, NY 11794, USA.

Oncotarget ; 8(32): 52935-52947, 2017 Aug 08.

Article en En | MEDLINE | ID: mdl-28881784

Palabras clave

Selective Inhibitors of Nuclear Export (SINE) compounds; arrestin related domain containing 3 (ARRDC3); exportin-1 (XPO-1); selinexor; triple negative breast cancer (TNBC)

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Oncotarget Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Oncotarget Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos